ACT-1004-1239
CXCR7 GPCR insurmountable antagonist target engagement in rodent, 61% F in dog from 300k HTS vs. β-arrestin recruitment, opt. J. Med. Chem., Dec. 14, 2020 Idorsia Pharma (Actelion), Allschwil, CH
Molecules of the Month - December 2020
Molecules of the Month
- OI338
- PF07059013
- AZD0364
- PF-06843195
- TP0586352
- AZD4573
- "compound 42"
- "compound 12"
- BMS-986202
- pamiparib
- linrodostat
- SAR439859
- ACT-1004-1239
- "compound 1"